herpeszoster60y.o.insufficientevidenceforscreening≥6.5%tamoxifen40-59 y.o.,ASCVD ≥10%, lowbleeding risk3%≥ 100mg/dL50y.o.≥ 126mg/dLFractureRiskAssessmentToolbreastcancer≥20%q1ydyslipidemiaovariancancer≤q2yoverweight/ obesityTyrer-Cuzickmodelcervicalcancercolorectalcancerraloxifene40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factorHepatitisBHIVTimedup andgo test40-70 y.o.,ASCVD ≥10%, lowbleeding riskq3y40y.o.40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factortobaccousearomataseinhibitorsPREVENTequation75y.o.multidoseinitial series,then 1 doseat 2-6months1 dose; 2doses (2-6monthsapart) ifimmunocomp≥ 140mg/dLstatinhypertension2 doses,2-6monthsapartq15ydiabetespneumococcal40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorsdepressionhormonetherapyq2yq5yHepatitisC≥5.7%community-dwelling,postmenopausalwomen52y.o.dementiaGailmodellungcanceranxietyq1-2ymammogrambased on lifeexpectancy /health status≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors65y.o.< 60y.o.cardiovasculardiseasewomenage 55-64 y.o.q1ymammogramaspirin≥ 200mg/dLherpeszoster60y.o.insufficientevidenceforscreening≥6.5%tamoxifen40-59 y.o.,ASCVD ≥10%, lowbleeding risk3%≥ 100mg/dL50y.o.≥ 126mg/dLFractureRiskAssessmentToolbreastcancer≥20%q1ydyslipidemiaovariancancer≤q2yoverweight/ obesityTyrer-Cuzickmodelcervicalcancercolorectalcancerraloxifene40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factorHepatitisBHIVTimedup andgo test40-70 y.o.,ASCVD ≥10%, lowbleeding riskq3y40y.o.40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factortobaccousearomataseinhibitorsPREVENTequation75y.o.multidoseinitial series,then 1 doseat 2-6months1 dose; 2doses (2-6monthsapart) ifimmunocomp≥ 140mg/dLstatinhypertension2 doses,2-6monthsapartq15ydiabetespneumococcal40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorsdepressionhormonetherapyq2yq5yHepatitisC≥5.7%community-dwelling,postmenopausalwomen52y.o.dementiaGailmodellungcanceranxietyq1-2ymammogrambased on lifeexpectancy /health status≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors65y.o.< 60y.o.cardiovasculardiseasewomenage 55-64 y.o.q1ymammogramaspirin≥ 200mg/dL

Untitled Bingo - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
  1. herpes zoster
  2. 60 y.o.
  3. insufficient evidence for screening
  4. ≥ 6.5%
  5. tamoxifen
  6. 40-59 y.o., ASCVD ≥ 10%, low bleeding risk
  7. 3%
  8. ≥ 100 mg/dL
  9. 50 y.o.
  10. ≥ 126 mg/dL
  11. Fracture Risk Assessment Tool
  12. breast cancer
  13. ≥ 20%
  14. q1y
  15. dyslipidemia
  16. ovarian cancer
  17. ≤ q2y
  18. overweight / obesity
  19. Tyrer-Cuzick model
  20. cervical cancer
  21. colorectal cancer
  22. raloxifene
  23. 40-75 y.o.; LDL > 190 or ASCVD ≥ 10% + ≥ 1 risk factor
  24. Hepatitis B
  25. HIV
  26. Timed up and go test
  27. 40-70 y.o., ASCVD ≥ 10%, low bleeding risk
  28. q3y
  29. 40 y.o.
  30. 40-75 y.o., ASCVD ≥ 7.5%, ≥ 1 risk factor
  31. tobacco use
  32. aromatase inhibitors
  33. PREVENT equation
  34. 75 y.o.
  35. multidose initial series, then 1 dose at 2-6 months
  36. 1 dose; 2 doses (2-6 months apart) if immunocomp
  37. ≥ 140 mg/dL
  38. statin
  39. hypertension
  40. 2 doses, 2-6 months apart
  41. q15y
  42. diabetes
  43. pneumococcal
  44. 40-75 y.o., LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  45. depression
  46. hormone therapy
  47. q2y
  48. q5y
  49. Hepatitis C
  50. ≥ 5.7%
  51. community-dwelling, postmenopausal women
  52. 52 y.o.
  53. dementia
  54. Gail model
  55. lung cancer
  56. anxiety
  57. q1-2y mammogram based on life expectancy / health status
  58. ≥ 40 y.o.; LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  59. 65 y.o.
  60. < 60 y.o.
  61. cardiovascular disease
  62. women age 55-64 y.o.
  63. q1y mammogram
  64. aspirin
  65. ≥ 200 mg/dL